The FDA has concerns with Axsome’s lead and potential blockbuster drug to treat major depressive disorder, which sent the company’s stock price down by more than 40% early Monday.

One week after reporting a late-stage failure for its lead drug, Axsome is back with positive news: In the 302-person Phase III INTERCEPT trial, its experimental migraine drug hit both primary endpoints: Stopping migraine pain entirely and preventing pain from progressing beyond ”mild intensity.”

The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.